Skip to the main content.

Spinal Muscular Atrophy

PEDIATRIC — PHASE 2

Case Studies

Here you can edit the background of the section

Key Takeaways

This study evaluated an investigational therapy for spinal muscular atrophy (SMA). To be eligible, participants had to be genetically diagnosed with SMA, presymptomatic and ≤ 6 weeks of age. 

As time was of the essence, the sponsor wanted to implement a comprehensive travel and reimbursement program that would eliminate the logistical and financial concerns that could prevent a family from participating in the study.

comprehensive travel and reimbursement

Challenges

Randomization needed to occur within six weeks of birth and before the newborn became symptomatic; therefore, educating the physician community about the study was critical.

Logistical and financial barriers had to be eliminated in order to ensure all potentially eligible patients could be considered for participation and, if enrolled, could participate for the duration of the study.

Complex travel support had to be managed (e.g., obtaining travel visas, facilitating cross-border travel and accelerated booking) during an emotionally difficult time for parents.





Solution and Impact

The study leveraged BBK TravelTM as an adaptive solution that could fit the needs of all travelers.

Over the course of the study, there were several instances where the program evolved to meet the needs of this unique pediatric population. Some instances called for a patient ambassador to assist with translation, medical care and transportation. Other instances called for special overnight accommodations outside of a traditional hotel stay.

In reducing the time it might take sites to do this coordination, site staff were freed up to focus on patient care.

 

  • Participants_ICON 19 ENROLLED PATIENTS

  • Calendar_ICON 22 MONTHS OF SUPPORT

  • Sites_ICON 17 SITES

  • Countries-ICON-1 11 COUNTRIES

Impact: Travel and Reimbursement

  • __BBK-WEBSITE-ICONS-2-12 772 Reimbursed Visits Over the course of the study, the site staff reimbursed families for 772 visits — including initial screening visits — contributing to overall study satisfaction. All families supported with a TCN Card payment and reimbursement program remained in the study for the duration.

  • __BBK-WEBSITE-ICONS-2-01 418 Travel Itineraries BBK’s Concierge specialists removed major barriers to participation by arranging full-service transportation (e.g., air, ground), hotel accommodations, visa assistance and translation.

Download the PDF version of this case study today:

Subscribe to stay connected

Share this page:

Familial Amyloid Polyneuropathy — Neurology and Gene Therapy — Phase 3

case-studies-icon Case Studies

March 23, 2023

Major Depressive Disorder — Mental Health — Pivotal Phase 3 Study

case-studies-icon Case Studies

March 23, 2023

Pediatric Boys with Duchenne Muscular Dystrophy — Rare and Gene Therapy — Phase 3B

case-studies-icon Case Studies

March 23, 2023

BBK Worldwide, LLC
117 Kendrick St., Suite 600
Needham, MA 02494 United States

        Terms & Conditions  Privacy Policy

        © 2023 BBK Worldwide. BBK Worldwide is a Publicis Health company.

        Facebook LinkedIn YouTube
        Facebook LinkedIn YouTube

        Terms & Conditions  Privacy Policy

        © 2023 BBK Worldwide. BBK Worldwide is a Publicis Health company.